Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down

Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.

    Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

    Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.

      Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

      Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.

        Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

        Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

          AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View

          AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.

            Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat

            Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.

              Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

              Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1

                Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.

                  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

                  Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

                    Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

                    Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

                      Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates

                      Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.

                        Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y

                        Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.

                          Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1

                          Bayer (BAYRY) misses first-quarter 2018 earnings and sales estimates.

                            Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

                            Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.

                              What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)

                              Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

                                What Lies Ahead for Ligand (LGND) This Earnings Season?

                                Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

                                  Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

                                  Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

                                    Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

                                    Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

                                      Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View

                                      Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.

                                        Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                                        Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                                          Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y

                                          Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.

                                            Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?

                                            Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?

                                              Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat

                                              Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.

                                                Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y

                                                The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.

                                                  Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

                                                  Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.